Investment Marks a Significant Milestone in Advancing AI-Based Arrhythmia Care
Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, announced a $16 million Series A investment co-led by Solas BioVentures and TVM Capital Life Science. This funding underscores investor confidence in Vektor’s vision and ability to successfully execute its mission to revolutionize arrhythmia care.
Recommended: CIO Influence Primer on Data Integration: Definition, Key Techniques, Tools and Examples
“The medical community is being confronted with the necessity for change. With an increasing atrial fibrillation (AF) patient population, outcomes must be improved while also enhancing procedure efficiency”
“The medical community is being confronted with the necessity for change. With an increasing atrial fibrillation (AF) patient population, outcomes must be improved while also enhancing procedure efficiency,” said Rob Krummen, CEO of Vektor Medical. “vMap presents a solution to this challenge. Leading electrophysiologists (EPs) around the U.S. are utilizing vMap to streamline ablation procedures and improve patient outcomes. With the investment from Solas and TVM, we can expand access to this groundbreaking technology.”
Recommended: Reviewing Major Cybersecurity Attacks and Resilience Strategies
Funding will support the commercialization of vMap, Vektor’s AI-based arrhythmia analysis tool, which is transforming how EPs approach ablation procedures. To bolster this expansion, Vektor will increase clinical support and drive additional clinical studies to showcase the technology’s impact and inform future innovation as well as continue efforts to secure reimbursement.
“At Solas, we invest in game-changing healthcare innovation and strong leadership teams committed to creating meaningful patient impact,” said Dr. David Adair, Managing Director of Solas BioVentures. “Vektor is addressing a massive problem in the cardiac arrhythmia space, giving millions of patients a chance to lead healthy lives free from this debilitating disease once again. We are thrilled to partner with the team and support Vektor’s unwavering commitment to challenging the status quo across the entire cardiac arrhythmia pathway, making it easier and faster for physicians and health systems to access this breakthrough technology.”
vMap is the only FDA-cleared, non-invasive AI-based solution for arrhythmia localization and analysis, utilizing a 12-lead ECG. vMap provides information to a physician to better understand arrhythmia sources and unlock actionable insights, enabling physicians to streamline their procedures and more appropriately treat their patients.
“Changing the standard of care demands a unique and transformative approach,” said Dr. Luc Marengère, Managing Partner at TVM Capital Life Science. “vMap has been embraced by EPs focused on excellence. With increased resources, Vektor will scale adoption across the US and Europe. Patients and healthcare providers deserve better and Vektor is ushering in that transition. We’re thrilled to invest and partner with Vektor to drive this important healthcare transformation.”
Recommended: 10 Things You Should Know About the Modern Data Infrastructure Dynamics in 2023
[To share your insights with us as part of editorial or sponsored content, please write to sghosh@martechseries.com]
